XANTATINA INHIBE LA ACTIVACIÓN DE MASTOCITOS INDUCIDA POR NEUROPÉPTIDOS PRO-INFLAMATORIOS
DOI:
https://doi.org/10.31051/1852.8023.v2.n1.13859Palabras clave:
Xanthanólido, sustancia P, neurotensina, xanthanolide, substance P, neurotensinResumen
Los mastocitos son células del tejido conectivo que participan en la génesis y modulación de las respuestas inflamatorias. Previamente hemos demos-trado que xanthatina (xanthanólido sesquiterpeno aislado de Xanthium cavanillesii Schouw) inhibe la activación de mastocitos inducida por secretagogos experimentales. Sin embargo, se desconoce su efecto sobre la activación de mastocitos inducida por estímulos fisiopatológicos. Estos estímulos incluyen, entre otros, los neuropéptidos pro-inflamatorios sustancia P y neurotensina, responsables de una de las principales vías de inflamación neurogénica. El objetivo del presente trabajo fue estudiar el efecto de xanthatina sobre la activación de mastocitos inducida por sustancia P y neurotensina. Mastocitos peritoneales de rata se incubaron con: 1) PBS (basal); 2) sustancia P (100 µm); 3) neurotensina (50 µm); 4) xanthatina (8-320 µm)+sustancia P; 5) xanthatina (8-320 µm)+neurotensina. Se llevaron a cabo los siguientes estudios: análisis dosis-respuesta de la liberación de serotonina inducida por neuropéptidos proinflamatorios, vitalidad celular, morfología mastocitaria por microscopía óptica y electrónica, análisis de estabilidad de xanthatina por cromatografía en capa fina. Los ensayos de liberación de serotonina y los estudios morfológicos mostraron la efectividad de xanthatina para estabilizar mastocitos. El presente estudio provee la primer evidencia a favor de la hipótesis de que xanthatina inhibe la liberación de serotonina inducida por sustancia P y neurotensina a partir de mastocitos peritoneales. Este sesquiterpeno podría representar una nueva alternativa fármacológica en la regulación de la activación mastocitaria para el tratamiento de las inflamaciones neurogénicas.
Mast cells are connective tissue cells involved in the genesis and modulation of inflammatory responses. We have previously shown that xanthatin (xanthanolide sesquiterpene isolated from Xanthium cavanillesii Schouw) inhibits mast cell activation induced by experimental secretagogues. However, the effect of xanthatin on mast cell activation induced by pathophysiological stimuli remains unknown. These stimuli include, among others, the pro-inflammatory neuropeptide substance P and neurotensin, responsible for one of the main pathways of neurogenic inflammation. The present study was designed to examine the effects of xanthatin on mast cell activation induced by pro-inflammatory peptides, such as substance P and neurotensin. Rat peritoneal mast cells were incubated with: 1) PBS (basal); 2) substance P (100 µm); 3) neurotensin (50 µm); 4) xanthatin (8-320 µm)+substance P; 5) xanthatin (8-320 µm)+neurotensin. Concentration-response studies of mast cell serotonin release evoked by pro-inflammatory neuropeptides, evaluation of mast cell viability and morphology by light and electron microscopy, and drug stability analysis by thin layer chromatography were performed. Serotonin release studies, carried out together with morphological studies, showed the effectiveness of xanthatin to stabilize mast cells. The present study provides the first strong evidence in favour of the hypothesis that xanthatin inhibits substance P - and neurotensin-induced serotonin release from peritoneal mast cells. Our findings may provide an insight into the design of novel pharmacological agents which may be used to regulate the mast cell response in neurogenic inflammation.
Referencias
U, Rivera J. 2004. The ins and outs of IgE-dependent mast cell exocytosis. Trends Immunol 25:266-273.
Calderón GM, Torres-López J, Lin T, Chavez B, Hernández M, Muñoz O, Befus AD, Enciso JA. 1998. Effects of toxin A from Clostridium difficile on mast cell activation and survival. Infect Immun 66:2755-2761.
Castagliuolo I, Wang CC, Valenick L, Pasha A, Nikulasson S, Carraway RE, Pothoulakis C. 1999. Neurotensin is a proinflammatory neuropeptide in colonic inflammation. J Clin Invest 103:843-849.
Dvorak AM. 2005. Ultrastructural studies of human basophils and mast cells. J Histochem Cytochem 53:1043-1070.
Favier LS, Maria AOM, Wendel GH, Borkowski EJ, Giordano OS, Pelzer L, Tonn CE. 2005. Anti-ulcerogenic activity of xanthanolide sesquiterpenes from Xanthium cavanillesii in rats. J Ethnopharmacol 100:260-267.
Galli SJ, Grimbaldeston M, Tsai M. 2008. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nature 8:478-486.
Giordano OS, Guerreiro E, Pestchanker MJ. 1990. The gastric cytoprotective effect of several sesquiterpene lactones. J Nat Prod 53:803-809.
Gurish MF, Austen KF. 2001. The diverse roles of mast cells. J Exp Med 194:F1-F5.
Kalesnikoff J, Galli SJ. 2008. New developments in mast cell biology. Nature Immunology 9:1215-1223.
Katsanos GS, Anogianaki A, Castellani ML, Ciampoli C, De Amicis D, Orso C, Pollice R, Vecchiet J, Tetè S, Salini V, Caraffa A, Patruno A, Shaik YB, Kempuraj D, Doyle R, Antinolfi PL, Cerulli G, Conti CM, Fulcheri M, Neri G, Sabatino G. 2008. Biology of neurotensin: revisited study. Int J Immunopathol Pharmacol 21:255-259.
Kawamoto K, Aoki J, Tanaka A, Itakura A, Hosono H, Arai H, Kiso Y, Matsuda H. 2002. Nerve growth factor activates mast cells through the collaborative interaction with lysophosphatidylserine expressed on the membrane surface of activated platelets. J Immunol 168:6412-6419.
Kim TD, Eddlestone GT, Mahmoud SF, Kuchtey J, Fewtrell C. 1997. Correlating Ca2+ responses and secretion in individual RBL-2H3 mucosal mast cells. J Biol Chem 272:31225-31229.
Kubes P, Granger DN. 1996. Leukocyte-endothelial cell interactions evoked by mast cells. Cardiovasc Res 32:699-708.
Kulka M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP. 2008. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 123:398-410.
Kushnir-Sukhov NM, Brown JM, Wu Y, Kirshenbaum A, Metcalfe DD. 2007. Human mast cells are capable of serotonin synthesis and release. J Allergy Clin Immunol 119:498-499.
Lawson D, Raff MC, Gomperts B, Fewtrell C, Gilula NB. 1977. Molecular events during membrane fusion. A study of exocytosis in rat peritoneal mast cells. J Cell Biol 72:242-259.
Moriyama M, Sato T, Inoue H, Fukuyama S, Teranishi H, Kangawa K, Kano T, Yoshimura A, Kojima M. 2005. The neuropeptide neuromedin U promotes inflammation by direct activation of mast cells. J Exp Med 202:217-24.
Penissi A, Rudolph I, Fogal T, Piezzi R. 2003a. Changes in duodenal mast cells in response to dehydroleucodine. Cells Tissues Organs 173:234-241.
Penissi AB, Fogal T, Guzmán JA, Piezzi RS. 1998. Gastroduodenal mucosal protection induced by dehydroleucodine. Mucus secretion and role of monoamines. Dig Dis Sci 43:791-798.
Penissi AB, Giordano OS, Guzmán JA, Rudolph MI, Piezzi RS. 2006. Chemical and pharmacological properties of dehydro-leucodine, a lactone isolated from Artemisia douglasiana Besser. Molecular Medicinal Chemistry 10:1-11.
Penissi AB, Mariani ML, Souto M, Guzmán JA, Piezzi RS. 2000. Changes on gastroduodenal 5-hydroxytryptamine-containing cells induced by dehydroleucodine. Cells, Tissues and Organs 166:259-266.
Penissi AB, Piezzi RS. 1999. Effect of dehydro-leucodine on mucus production. A quantitative study. Dig Dis Sci 44:708-712.
Penissi AB, Rudolph MI, Piezzi RS. 2003b. Gastrointestinal mucosal protection induced by dehydroleucodine: role of mast cells (review). Biocell 27:163-172.
Penissi AB, Rudolph MI, Villar M, Coll RC, Fogal TH, Piezzi RS. 2003c. Effect of dehydro-leucodine on histamine and serotonin release from mast cells in the isolated mouse jejunum. Inflamm Res 52:199-205.
Penissi AB, Vera ME, Mariani ML, Rudolph MI, Ceñal JP, de Rosas JC, Fogal TH, Tonn CE, Favier LS, Giordano OS, Piezzi RS. 2009. Novel anti-ulcer alpha,beta-unsaturated lactones inhibit compound 48/80-induced mast cell degranulation. Eur J Pharmacol 612:122-130.
Pickett JA, Edwardson JM. 2006. Compound exocytosis: mechanisms and functional significance. Traffic 7:109-116.
Rao KN, Brown MA. 2008. Mast cells: multifaceted immune cells with diverse roles in health and disease. Ann N Y Acad Sci 1143:83-104.
Richardson JD, Vasko MR. 2002. Cellular mechanisms of neurogenic inflammation. J Pharmacol Exp Ther 302:839-845.
Schäffer M, Beiter T, Becker HD, Hunt TK. 1998. Neuropeptides: mediators of inflammation and tissue repair? Arch Surg. 133:1107-1116,
Schmelz M, Petersen LJ. 2001. Neurogenic inflammation in human and rodent skin. News Physiol Sci 16:33-37.
Taylor AM, Galli SJ, Coleman JW. 1995. Stem-cell factor, the kit ligand, induces direct degranulation of rat peritoneal mast cells in vitro and in vivo: dependence of the in vitro effect on period of culture and comparisons of stem-cell factor with other mast cell-activating agents. Immunology 86: 427-433.
Wagner J, Vitali P, Palfreyman MG, Zraika M and Huot S. 1982. Simultaneous determination of 3,4-dihydroxyphenylalanine, 5-hydroxy-tryptophan, dopamine, 4-hydroxy-3-methoxyphenylalanine, norepinephrine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, 5-hydroxytryptamine, and 5-hydroxyindole-acetic acid in rat cerebrospinal fluid and brain by high performance liquid chromatography with electrochemical detection. J Neurochem 38:1241-1254.
Descargas
Publicado
Número
Sección
Licencia
Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista. Su utilización estará restringida a fines no comerciales.
Una vez aceptado el manuscrito para publicación, los autores deberán firmar la cesión de los derechos de impresión a la Asociación Argentina de Anatomía Clínica, a fin de poder editar, publicar y dar la mayor difusión al texto de la contribución.
